Brian Leber

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10529385/publications.pdf

Version: 2024-02-01

78 papers	7,255 citations	109321 35 h-index	88630 70 g-index
81 all docs	81 docs citations	81 times ranked	8882 citing authors

#	Article	IF	Citations
1	BCRâ€“ABL1 transcript doubling time as a predictor for treatmentâ€free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. British Journal of Haematology, 2022, 196, 136-145.	2.5	4
2	Efficacy and specificity of inhibitors of BCL-2 family protein interactions assessed by affinity measurements in live cells. Science Advances, 2022, 8, eabm7375.	10.3	9
3	Abnormal dopamine receptor signaling allows selective therapeutic targeting of neoplastic progenitors in AML patients. Cell Reports Medicine, 2021, 2, 100202.	6.5	5
4	Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario. Current Oncology, 2021, 28, 1376-1387.	2.2	7
5	Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients. Cell Reports, 2021, 34, 108845.	6.4	3
6	Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study. Blood, 2021, 138, 66-66.	1.4	7
7	Fitness Assessment of Elderly Patients with AML and Outcomes. Blood, 2021, 138, 3379-3379.	1.4	0
8	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine, 2020, 383, 617-629.	27.0	1,407
9	Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leukemia and Lymphoma, 2020, 61, 3287-3305.	1.3	2
10	Revised 15-item MDS-specific frailty scale maintains prognostic potential. Leukemia, 2020, 34, 3434-3438.	7.2	8
11	Allosteric Regulation of BH3 Proteins in Bcl-xL Complexes Enables Switch-like Activation of Bax. Molecular Cell, 2020, 77, 901-912.e9.	9.7	32
12	The carboxyl-terminal sequence of bim enables bax activation and killing of unprimed cells. ELife, 2020, 9, .	6.0	30
13	Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.. Journal of Clinical Oncology, 2020, 38, e20011-e20011.	1.6	0
14	Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. Leukemia and Lymphoma, 2019, 60, 3493-3502.	1.3	5
15	Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment NaÃ¯ve Myelofibrosis Patients. Blood, 2019, 134, 4164-4164.	1.4	21
16	Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2. ELife, 2019, 8, .	6.0	43
17	A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Advances, 2018, 2, 1935-1945.	5.2	34
18	Unleashing Blocked Apoptosis in Cancer Cells: New MCL1 Inhibitors Find Their Groove. Cancer Discovery, 2018, 8, 1511-1514.	9.4	3

#	Article	IF	Citations
19	Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence. Cancer Cell, 2018, 34, 483-498.e5.	16.8	125
20	Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Reports, 2018, 19, .	4.5	56
21	Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available. Blood, 2018, 132, 1774-1774.	1.4	3
22	Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-NaÃ¯ve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study. Blood, 2018, 132, 5548-5548.	1.4	9
23	Sam68 Allows Selective Targeting of Human Cancer Stem Cells. Cell Chemical Biology, 2017, 24, 833-844.e9.	5.2	38
24	A Small-Molecule Inhibitor of Bax and Bak Oligomerization Prevents Genotoxic Cell Death and Promotes Neuroprotection. Cell Chemical Biology, 2017, 24, 493-506.e5.	5.2	76
25	Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche. Nature Cell Biology, 2017, 19, 1336-1347.	10.3	150
26	Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. Oncotarget, 2016, 7, 72608-72621.	1.8	15
27	Gender and <scp>BCR</scp>â€<scp>ABL</scp> transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia. European Journal of Haematology, 2016, 96, 360-366.	2.2	35
28	Small molecules reveal an alternative mechanism of Bax activation. Biochemical Journal, 2016, 473, 1073-1083.	3.7	26
29	High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood, 2016, 128, 934-947.	1.4	104
30	Laboratory Investigation of Myeloproliferative Neoplasms (MPNs). American Journal of Clinical Pathology, 2016, 146, 408-422.	0.7	30
31	Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations. Stem Cells, 2015, 33, 1839-1849.	3.2	14
32	Distinct lipid effects on tBid and Bim activation of membrane permeabilization by pro-apoptotic Bax. Biochemical Journal, 2015, 467, 495-505.	3.7	54
33	Molecular Pathways: Leveraging the BCL-2 Interactome to Kill Cancer Cellsâ€"Mitochondrial Outer Membrane Permeabilization and Beyond. Clinical Cancer Research, 2015, 21, 2671-2676.	7.0	30
34	Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 715-727.	0.4	7
35	Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs. Journal of Experimental Medicine, 2014, 211, 1925-1935.	8.5	75
36	Examining the Molecular Mechanism of Bcl-2 Family Proteins at Membranes by Fluorescence Spectroscopy. Methods in Enzymology, 2014, 544, 1-23.	1.0	26

#	Article	IF	Citations
37	Regulating cell death at, on, and in membranes. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2100-2113.	4.1	61
38	The Proapoptotic Protein tBid Forms Both Superficially Bound and Membrane-Inserted Oligomers. Biophysical Journal, 2014, 106, 2085-2095.	0.5	20
39	Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood, 2014, 124, 729-736.	1.4	84
40	Bcl-2 Family and Their Therapeutic Potential. , 2014, , 61-96.		3
41	Patient Related Factors Have an Indepedent Impact on Overall Survival in Myelodysplastic Syndrome Patients: A Report of the MDS-Can Registry. Blood, 2014, 124, 165-165.	1.4	1
42	Mechanisms of Action of Bcl-2 Family Proteins. Cold Spring Harbor Perspectives in Biology, 2013, 5, a008714-a008714.	5.5	555
43	tBid Undergoes Multiple Conformational Changes at the Membrane Required for Bax Activation. Journal of Biological Chemistry, 2013, 288, 22111-22127.	3.4	79
44	A New Form Of Therapeutic Resistance: Drug Glucuronidation Regulated By The Sonic Hedgehog Factor Gli1. Blood, 2013, 122, 821-821.	1.4	0
45	Interactions of pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins measured in live MCF-7 cells using FLIM FRET. Cell Cycle, 2012, 11, 3536-3542.	2.6	33
46	Shedding Light on Apoptosis at Subcellular Membranes. Cell, 2012, 151, 1179-1184.	28.9	69
47	Differences in the Mechanisms of Proapoptotic BH3 Proteins Binding to Bcl-XL and Bcl-2 Quantified in Live MCF-7 Cells. Molecular Cell, 2012, 45, 754-763.	9.7	82
48	Interaction of the full-length Bax protein with biomimetic mitochondrial liposomes: A small-angle neutron scattering and fluorescence study. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 384-401.	2.6	24
49	Identification of Drugs IncludingÂa DopamineÂReceptor Antagonist that Selectively Target Cancer Stem Cells. Cell, 2012, 149, 1284-1297.	28.9	420
50	Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After â‰¥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results. Blood, 2012, 120, 694-694.	1.4	3
51	BH3-only proteins: Orchestrators of apoptosis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 508-520.	4.1	286
52	Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After â‰¥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib. Blood, 2011, 118, 606-606.	1.4	3
53	Pre-Screening for Low Methyl Guanine Methyltransferase (MGMT) Expression Results in High Response Rates to Temozolomide (TMZ) Therapy in AML and MDS Patients.. Blood, 2011, 118, 422-422.	1.4	0
54	A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase. Blood, 2011, 118, 4437-4437.	1.4	0

#	Article	IF	Citations
55	The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood, 2010, 116, 1433-1442.	1.4	55
56	Apoptosis: embedded in membranes. Current Opinion in Cell Biology, 2010, 22, 845-851.	5.4	65
57	Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Reviews in Molecular Medicine, 2010, 12, e28.	3.9	79
58	Identification of AML and MDS Patients Who Could Potentially Benefit From Temozolomide Therapy: Proportion of Patients with Low Methyl Guanine Methyltransferase (MGMT) Expression Level. Blood, 2010, 116, 3985-3985.	1.4	1
59	Differential Dependence On Wnt Signaling Allows Chemical Mediated Eradication of Human Acute Leukemia without Affecting Normal Blood Stem Cells. Blood, 2010, 116, 3278-3278.	1.4	4
60	BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38â^' cells, through activation of protein kinase Cî². Blood, 2009, 114, 4186-4196.	1.4	46
61	Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia.. Blood, 2009, 114, 2085-2085.	1.4	1
62	Spectral Analysis of Platelet Oscillations in Cyclic Thrombocytopenia.. Blood, 2009, 114, 4459-4459.	1.4	0
63	Bcl-XL Inhibits Membrane Permeabilization by Competing with Bax. PLoS Biology, 2008, 6, e147.	5.6	266
64	Membrane Binding by tBid Initiates an Ordered Series of Events Culminating in Membrane Permeabilization by Bax. Cell, 2008, 135, 1074-1084.	28.9	511
65	Embedded together: The life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 897-911.	4.9	327
66	Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO Journal, 2006, 25, 2287-2296.	7.8	229
67	Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer, 2006, 6, 213.	2.6	86
68	Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO Journal, 2005, 24, 2096-2103.	7.8	337
69	There is more to life and death than mitochondria: Bcl-2 proteins at the endoplasmic reticulum. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1644, 115-123.	4.1	52
70	During Apoptosis Bcl-2 Changes Membrane Topology at Both the Endoplasmic Reticulum and Mitochondria. Molecular Cell, 2004, 14, 523-529.	9.7	98
71	Interaction with a Membrane Surface Triggers a Reversible Conformational Change in Bax Normally Associated with Induction of Apoptosis. Journal of Biological Chemistry, 2003, 278, 48935-48941.	3.4	177
72	Endoplasmic reticulum localized Bcl-2 prevents apoptosis when redistribution of cytochrome c is a late event. Oncogene, 2001, 20, 1939-1952.	5.9	117

#	Article	IF	Citations
73	Myc Potentiates Apoptosis by Stimulating Bax Activity at the Mitochondria. Molecular and Cellular Biology, 2001, 21, 4725-4736.	2.3	126
74	Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene, 2000, 19, 329-336.	5.9	322
75	Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts. Oncogene, 1999, 18, 3520-3528.	5.9	61
76	At the onset of transformation polyomavirus middle-T recruits shc and src to a perinuclear compartment coincident with condensation of endosomes. Oncogene, 1998, 17, 565-576.	5.9	10
77	Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: Characterization of additional microgranular variants. , 1997, 56, 131-142.		51
78	Telomeres and Telomerase in Normal and Malignant Haematologic Cells. Leukemia and Lymphoma, 1996, 24, 1-9.	1.3	15